Billions of people lack access to timely diagnostics. A space-tested technology backed by NASA and the National Institutes of Health aims to fix that, and is close to being registered with the Food and Drug Administration

NASA had a problem. She needed a way to ensure astronauts stayed healthy while in space, since there were no doctors or laboratories available to perform blood tests.

Here on Earth, more than half of the world’s population faces the same problem. The World Health Organization estimates that 4.5 billion people lack access to timely diagnostic tests, with doctors often taking weeks to interpret results. This means delays in care for more than 194 million American adults with chronic diseases.

Possible solution to both issues? health Home diagnostic kits deliver lab-quality results in up to 20 minutes from a self-collected blood sample.

This patented technology has been tested on the International Space Station and is now being adapted for care settings and eventually private homes.

With technology, the ability to perform more than 100 tests in a single device, and support from NASA and the National Institutes of Health, rHEALTH aims to disrupt the $323 billion blood diagnostics market.

FDA registration is targeted within approximately 12 months.

Backed by science

the health ONE was tested aboard the International Space Station by astronaut Samantha Cristoforetti in some of the most extreme conditions.

Results of this technology have been published in top peer-reviewed scientific journals, and were specifically selected by NASA after reviewing competing diagnostic platforms for space use.

The system was also founded by a Harvard/MIT-trained doctor who invested $2 million of his personal money in the company. There are 17 US patents covering device architecture, diagnostic algorithms and miniaturized components.

Strategic partnerships have been launched with Mayo Clinic, Boston Children’s Hospital, Massachusetts General Hospital, NASA, the National Institutes of Health, and AstraZeneca. rHEALTH has also been awarded more than $20 million in non-dilutive financing based on its technical feasibility and merit.

Take advantage of global health trends

health Operating in multi-billion dollar markets:

• A potentially $16.2 billion market focused on blood disease diagnostics
• A $224 billion serviceable market focused on laboratory, point-of-care and home testing
• The global market for diagnostics and patient monitoring is worth $323 billion

With more than 500 million blood tests performed each year in the United States alone, there is a growing need for accessible diagnostic tools and decentralized care.

rHEALTH plans to use complementary revenue streams to support primary and recurring revenue: hardware sales, test cartridges, and software subscriptions.

Own a piece of space-tested technology

The World Health Organization has historically called for increased access to diagnostic tools.

However, most tools only test one condition. This means many tests, blood draws and appointments that billions of people around the world cannot access. Even then, laboratories and clinicians are often required to process and interpret the results.

rHealth is a single platform with the capacity to perform over 100 tests, and is designed to continue expanding, much like a diagnostics app store.
Full information is available at https://www.startengine.com/offering/rhealth.

This Reg CF offering is provided by StartEngine Primary, LLC, Member FINRA/SIPC. This investment is considered speculative, illiquid and involves a high level of risk, including the possibility of losing your entire investment.

Benzinga is compensated to publish this content. Please read our 17B Disclosures here.